PepGen Inc. Prices $125 Million Public Offering to Advance Rare Disease Pipeline
PepGen Inc. (PEPG) prices a $125 million public offering of 25 million shares at $5.00 each to fund its EDO technology and myotonic dystrophy type 1 clinical trials.
ALFA USA News
Straight from the SEC filing
Every SEC filing by PepGen Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (12 Nov 2026). Not a valuation or a recommendation.
Up 55.2% over the last month ($2.70 on 19 Oct → $4.19 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $2.70 |
|---|---|
| 20 Oct | $2.87 |
| 21 Oct | $2.72 |
| 22 Oct | $2.70 |
| 23 Oct | $2.52 |
| 26 Oct | $2.49 |
| 27 Oct | $2.60 |
| 28 Oct | $2.53 |
| 29 Oct | $2.41 |
| 30 Oct | $2.36 |
| 2 Nov | $2.35 |
| 3 Nov | $2.46 |
| 4 Nov | $2.45 |
| 5 Nov | $2.32 |
| 6 Nov | $2.47 |
| 9 Nov | $2.39 |
| 10 Nov | $4.61 |
| 11 Nov | $5.26 |
| 12 Nov | $5.04 |
| 13 Nov | $4.36 |
| 16 Nov | $4.19 |
PepGen Inc. (PEPG) prices a $125 million public offering of 25 million shares at $5.00 each to fund its EDO technology and myotonic dystrophy type 1 clinical trials.
PepGen Inc. (PEPG) reported positive Phase 2 results for PGN-EDODM1, achieving 46.5% splicing correction in DM1 patients and securing funding into 2028.
Track PepGen Inc. live
Get the next PepGen Inc. SEC filing seconds after it lands.